Ironwood Pharmaceuticals Coverage Initiated by Analysts at Leerink Swann (IRWD)
Research analysts at Leerink Swann started coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) in a report released on Monday, American Banking & Market News reports. The firm set a “market perform” rating on the stock.
A number of other firms have also recently commented on IRWD. Analysts at BMO Capital Markets initiated coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) in a research note to investors on Monday. They set a “market perform” rating on the stock. Separately, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) in a research note to investors on Tuesday, September 17th. They set a “sell” rating on the stock. Finally, analysts at Mizuho cut their price target on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from $23.00 to $16.00 in a research note to investors on Wednesday, September 11th. They now have a “buy” rating on the stock.
Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.16.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 12.10 on Monday. Ironwood Pharmaceuticals has a one year low of $9.83 and a one year high of $19.67. The stock has a 50-day moving average of $12.00 and a 200-day moving average of $13.74. The company’s market cap is $1.373 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings data on Tuesday, July 23rd. The company reported ($0.57) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.70) by $0.13. The company had revenue of $9.70 million for the quarter, compared to the consensus estimate of $6.32 million. During the same quarter last year, the company posted ($0.38) earnings per share. Ironwood Pharmaceuticals’s revenue was down 33.6% compared to the same quarter last year. Analysts expect that Ironwood Pharmaceuticals will post $-2.54 EPS for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.